HKSE - Delayed Quote HKD

JACOBIO-B (1167.HK)

3.960

+0.320

+(8.79%)

At close: May 9 at 4:08:05 PM GMT+8

Jacobio Pharmaceuticals Group And 2 Other Promising Penny Stocks In Global

Global markets have been experiencing significant volatility due to escalating trade tensions, particularly between the U.S. and China, which has affected investor sentiment and led to fluctuations in major indices. For investors interested in exploring opportunities beyond the mainstream market, penny stocks—though an older term—remain a relevant area of investment that can offer both affordability and growth potential. These stocks typically represent smaller or newer companies, and when...

Simply Wall St. 24 days ago

OV8.SI

JBPHF
Jacobio Pharma Announces 2024 Annual Results

Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows. By the end of 2024, cash and bank balances and bank credit balances amounted to RMB1.45 billion. Jacobio also announced recent business progress and expected milestones.

PR Newswire last month

JBPHF
Asian Market Insights: Jacobio Pharmaceuticals Group Among 3 Promising Penny Stocks

As global markets grapple with economic uncertainties, including policy risks and inflation concerns, investors are increasingly looking toward Asia for opportunities. Penny stocks, though often considered niche investments, can offer significant growth potential when backed by strong financials. In this article, we explore three promising penny stocks in Asia that combine financial strength with the potential for long-term success.

Simply Wall St. 2 months ago

JBPHF

2469.HK

H22.SI
February 2025's Top Penny Stocks To Watch

Global markets have recently experienced a mix of volatility and growth, with U.S. stocks facing challenges from competitive pressures in the AI sector and political uncertainties surrounding tariffs, while European markets have been buoyed by strong earnings and interest rate cuts. In such fluctuating conditions, investors may find opportunities in lesser-known areas like penny stocks—an investment category that remains relevant despite its old-fashioned name. These smaller or newer...

Simply Wall St. 3 months ago

JBPHF
The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been published in Nature Medicine (impact factor 58.7). In the article, Jaocbio disclosed, for the first time, the complete dataset of glecirasib in KRAS G12C mutant non-small cell lung cancer patients in the second line or above setting.

PR Newswire 4 months ago

JBPHF
Meriaura Group Oyj And 2 Other Promising Penny Stocks

As global markets navigate a complex landscape marked by fluctuating consumer confidence and mixed economic indicators, investors are exploring diverse opportunities for growth. Penny stocks, although an older term, remain significant as they often represent smaller or newer companies with the potential for substantial returns when supported by strong financials. In this article, we will examine three penny stocks that demonstrate balance sheet strength and long-term potential, offering...

Simply Wall St. 4 months ago

2HRA.DE

JBPHF

MERIS.ST
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting in San Diego, California.

PR Newswire 4 months ago

JBPHF
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted the China rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals Co., Ltd (688578.SH).

PR Newswire 8 months ago

JBPHF
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combination with a SHP2 inhibitor (JAB-3312) in frontline non-small cell lung cancer (NSCLC) patients harboring KRAS G12C mutation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting as form of oral presentation. Jacobio also presented updated data of pivotal phase II study of glecirasib as form of oral presenta

PR Newswire 11 months ago

JBPHF

Performance Overview

Return	1167.HK	HANG SENG INDEX (^HSI)
YTD	+211.81%	+14.00%
1-Year	+97.01%	+23.36%
3-Year	-46.20%	+14.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

JACOBIO-B (1167.HK)

Jacobio Pharmaceuticals Group And 2 Other Promising Penny Stocks In Global

Jacobio Pharma Announces 2024 Annual Results

Asian Market Insights: Jacobio Pharmaceuticals Group Among 3 Promising Penny Stocks

February 2025's Top Penny Stocks To Watch

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

Meriaura Group Oyj And 2 Other Promising Penny Stocks

Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO

Performance Overview